Among these, lentivirus-based vectors, derived from the HIV-1 retrovirus, are of growing interest in gene and cell therapy, particularly in immuno-oncology, due to their ability to infect dividing ...

They are ideal for labeling cell types that are difficult to label using BacMam, lentivirus or other transfection-based labeling approaches (e.g. immune cells and primary cells). These dyes can be ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...